Department of General Practice, Claude Bernard Lyon 1 University, 8 avenue Rockefeller, 69373, Lyon Cedex 08, France.
Department of General Practice, University of Poitiers, Poitiers, France.
Eur J Clin Pharmacol. 2024 Oct;80(10):1593-1595. doi: 10.1007/s00228-024-03716-3. Epub 2024 Jul 17.
Cough is a prevalent symptom driving patients to seek medical attention in general practice. Despite its widespread use, the clinical efficacy of oxomemazine, the second most reimbursed molecule in France for symptomatic cough treatment, remains uncertain. This study aims to systematically evaluate the clinical efficacy of oxomemazine in cough.
A systematic literature review with meta-analysis of randomized controlled trials (RCTs) was conducted according to the Rebuild the Evidence Base (REB) protocol. Clinical trials comparing the efficacy of oxomemazine versus placebo or active comparator in cough were searched for. Trials with insufficient data were excluded. Searches were conducted across major databases (Medline, Cochrane Central Register of Controlled Trials, and Embase) and trial registries (World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov). RCTs comparing oxomemazine versus placebo or active comparators in cough were sought. Risk of bias was assessed using the Cochrane Collaboration's RoB2 tool. The protocol was preregistered on PROSPERO under the number CRD42022345496 (15). This study received no funding.
No RCTs were at low risk of bias. Therefore, no meta-analysis was conducted, in accordance to the pre-specified protocol.
This systematic review highlights the lack of evidence regarding the efficacy of oxomemazine in cough treatment and underscores the need for further well-designed clinical trials to inform its clinical utility in primary care settings.
咳嗽是患者在全科医疗中寻求医疗关注的常见症状。尽管奥沙米嗪在法国被广泛用于治疗症状性咳嗽，且是报销第二多的药物，但它的临床疗效仍不确定。本研究旨在系统评估奥沙米嗪治疗咳嗽的临床疗效。
根据重建证据基础（REB）方案，进行了系统的文献回顾和随机对照试验（RCT）的荟萃分析。检索了比较奥沙米嗪与安慰剂或阳性对照药治疗咳嗽疗效的 RCT。排除了数据不足的试验。在主要数据库（Medline、Cochrane 中央对照试验注册库和 Embase）和试验注册库（世界卫生组织国际临床试验注册平台和 ClinicalTrials.gov）中进行了检索。寻找比较奥沙米嗪与安慰剂或阳性对照药治疗咳嗽的 RCT。使用 Cochrane 协作的 RoB2 工具评估偏倚风险。该方案已在 PROSPERO 上预先注册，编号为 CRD42022345496（15）。本研究没有资金支持。
没有 RCT 被认为是低偏倚风险的。因此，根据预先指定的方案，没有进行荟萃分析。
本系统评价强调了缺乏关于奥沙米嗪治疗咳嗽疗效的证据，并突出了需要进一步进行精心设计的临床试验，以了解其在初级保健环境中的临床实用性。
